UK AbbVie case augurs single EU medicines market
This article was originally published in Scrip
A victory in the UK Court of Appeal for parallel trader Chemistree against AbbVie could be a step towards a European single market for pharmaceuticals and help reduce drug shortages, said the law firm that represents Chemistree, Matthew Arnold & Baldwin. The case could have important ramifications for EU competition law and how pharma firms manage their supply chains.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.